Insights from the molecular docking analysis of SGLT2 and FIMH to combat uropathogenicity

SGLT2 inhibitors are a novel class of FDA approved anti-diabetes drugs. They act by blocking the SGLT2 protein, which prevents glucose reabsorption, leading in enhance glucose excretion and lower blood glucose levels. In diabetic patients, SGLT2 inhibitors have been linked to urinary tract infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdulaal, Wesam H, Bakhrebah, Muhammed A, Nassar, Majed S, Almazni, Ibrahim Abdullah, Almutairi, Wael Abdullah, Natto, Zuhair S, Khattab, Amin K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Biomedical Informatics 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484699/
https://www.ncbi.nlm.nih.gov/pubmed/37693079
http://dx.doi.org/10.6026/973206300181044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484699/
https://www.ncbi.nlm.nih.gov/pubmed/37693079
http://dx.doi.org/10.6026/973206300181044

Ejemplares similares